[1] |
Larocca CA, LeBoeuf NR. Overview of cutaneous T⁃cell lymphomas[J]. Hematol Oncol Clin North Am, 2019,33(4):669⁃686. doi: 10.1016/j.hoc.2019.04.004.
|
[2] |
陈浩, 孙建方, 周小鸽. 原发皮肤淋巴组织增殖性疾病分类进展[J]. 中华皮肤科杂志, 2019,52(9):647⁃651. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.013.
|
[3] |
Wilcox RA. Cutaneous B⁃cell lymphomas: 2016 update on diagnosis, risk⁃stratification, and management[J]. Am J Hematol, 2016,91(10):1052⁃1055. doi: 10.1002/ajh.24462.
|
[4] |
Graeppi⁃Dulac J, Vlaeminck⁃Guillem V, Perier⁃Muzet M, et al. Endocrine side⁃effects of anti⁃cancer drugs: the impact of retinoids on the thyroid axis[J]. Eur J Endocrinol, 2014,170(6):R253⁃262. doi: 10.1530/EJE⁃13⁃0920.
|
[5] |
Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T⁃cell lymphoma (mycosis fungoides)[J]. Arch Dermatol, 1987,123(2):201⁃204.
|
[6] |
Zhang M, Tao Y, Ma P, et al. Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma[J]. Anticancer Agents Med Chem, 2015,15(9):1204⁃1212. doi: 10.2174/187152 0615666150520142719.
|
[7] |
杨林芳, 曹玉萍, 张孟丽, 等. 新型维A酸ECPIRM及全反式维A酸对白细胞介素17刺激HaCaT细胞白细胞介素1β表达的影响[J]. 中华皮肤科杂志, 2015,48(11):797⁃800. doi: 10.3760/cma.j.issn.0412⁃4030.2015.11.011.
|
[8] |
Li H, Wang C, Ma P, et al. The retinoid derivant ECPIRM selectively exhibited anti⁃proliferation effects in cutaneous T⁃cell lymphoma via ITK⁃mediated signaling pathway[J]. J Dermatol Sci, 2020,97(3):208⁃215. doi: 10.1016/j.jdermsci.2020.01.013.
|
[9] |
Yang H, Ma P, Cao Y, et al. ECPIRM, a potential therapeutic agent for cutaneous T⁃cell lymphoma, inhibits cell proliferation and promotes apoptosis via a JAK/STAT pathway[J]. Anticancer Agents Med Chem, 2018,18(3):401⁃411. doi: 10.2174/1871520617666170327115657.
|
[10] |
Sadik A, Somarribas Patterson LF, Öztürk S, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression[J]. Cell, 2020,182(5):1252⁃1270.e34. doi: 10.1016/j.cell.2020.07.038.
|
[11] |
Weng M, Zhang H, Hou W, et al. ACAT2 promotes cell proliferation and associates with malignant progression in colorectal cancer[J]. Onco Targets Ther, 2020,13:3477⁃3488. doi: 10.2147/OTT.S238973.
|
[12] |
Zhao L, Fan J, Xia S, et al. HMG⁃CoA synthase 1 is a synthetic lethal partner of BRAF (V600E) in human cancers[J]. J Biol Chem, 2017,292(24):10142⁃10152. doi: 10.1074/jbc.M117.788 778.
|
[13] |
Seshacharyulu P, Rachagani S, Muniyan S, et al. FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis[J]. Oncogene, 2019,38(26):5265⁃5280. doi: 10.1038/s41388⁃019⁃0791⁃9.
|
[14] |
Kim BK, Yoo HI, Lee AR, et al. Decreased expression of VLDLR is inversely correlated with miR⁃200c in human colorectal cancer[J]. Mol Carcinog, 2017,56(6):1620⁃1629. doi: 10.1002/mc.22618.
|
[15] |
张孟丽, 魏峻, 马鹏程, 等. 维A酸衍生物ECPIRM对维A酸核受体的影响及小鼠皮肤刺激反应[J]. 中华皮肤科杂志, 2016,49(6):420⁃424. doi: 10.3760/cma.j.issn.0412⁃4030.2016. 06.013.
|